Drug Price Trends for NDC 50268-0606

Average Pharmacy Cost for 50268-0606

Drug Name	NDC	Price/Unit ($)	Unit	Date
SACUBITRIL-VALSARTAN 24-26 MG	50268-0606-11	0.62590	EACH	2026-04-01
SACUBITRIL-VALSARTAN 24-26 MG	50268-0606-15	0.62590	EACH	2026-04-01

Best Wholesale Price for NDC 50268-0606

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 50268-0606

Last updated: April 4, 2026

What Is NDC 50268-0606?

NDC 50268-0606 corresponds to Keytruda (pembrolizumab), a PD-1 inhibitor manufactured by Merck. It is approved for multiple indications, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and others.

Market Size and Trends

Current Market Landscape

• Global Oncology Drug Market: Valued at approximately $156 billion in 2022, expected to grow at a CAGR of 7% through 2030 [1].
• Keytruda Revenues: Posted $22.9 billion in sales for 2022, representing a 20% year-over-year increase [2].
• Indication Expansion: Added over 10 new approvals since 2019, broadening its revenue base.

Competitive Landscape

Drug	Indications	2022 Sales (USD billion)	Market Share (%)
Keytruda	Multiple cancers	22.9	48
Opdivo	Melanoma, lung, kidney	6.8	14
Tecentriq	Lung, breast	3.1	7
Imfinzi	Lung, bladder	3.2	7

Market Drivers

• Expansion into new indications increases addressable market.
• Growing adoption in combination therapies.
• Rising global cancer incidence: estimated 19.3 million cases worldwide in 2020, projected to rise annually [3].

Key Challenges

• High treatment costs: average list price exceeds $10,000 per dose.
• Competition from biosimilars not expected soon, but patent expiries and legal challenges may influence pricing strategies.

Price Projections

Current Pricing

• List price: approximately $7,000 to $10,000 per dose; treatment course averages $150,000 to $200,000 depending on indication.
• Commercial reimbursement rates vary by region and insurer, with negotiated discounts reducing actual paid amounts.

Projections (Next 5 Years)

Year	Projected Revenue (USD billion)	Assumptions
2023	$25	Continued indication approvals, stable pricing, increased adoption
2024	$27	Broadened use, increased global access
2025	$30	New indications, combination therapy uptake
2026	$33	Competitive pressure and pricing adjustments
2027	$35	Patent protection, minimal biosimilar impact

Price Sensitivity

• Newer indications and combinations tend to command premium pricing.
• Price erosion likely as biosimilars or generics approach, particularly in mature markets.
• Discounting expected in emerging markets to improve access.

Strategic Implications

• Investment in pipeline expansion, focusing on novel immunotherapies.
• Licensing and partnership opportunities to leverage new indications.
• Monitoring patent expiry dates to mitigate generic competition impacts.

Key Takeaways

• NDC 50268-0606 (Keytruda) maintains a dominant market position with projected revenues to grow from $25 billion in 2023 to $35 billion in 2027.
• Price per dose remains high but faces downward pressure from market competition and biosimilar entries projected after 2028.
• Expansion into new indications and global markets is critical for sustaining revenue growth.
• Cost management and partnership strategies are key to navigating future pricing landscape.

FAQs

1. When does the patent for Keytruda expire?
   Patent protections expire gradually, with key patents expiring around 2028–2030, opening potential for biosimilar competition.

2. What are the primary indications for NDC 50268-0606?
   Melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and several others.

3. How does Keytruda's pricing compare to competitors?
   Its list price exceeds that of some competitors but is similar to other monoclonal antibodies used in oncology.

4. What factors could affect future pricing?
   Patent expiries, biosimilar entry, reimbursement policies, and competitive developments.

5. Are there upcoming regulatory decisions impacting Keytruda?
   Several supplemental approvals and label expansions are anticipated through 2024, potentially expanding markets and revenue.

---

Sources

[1] Markets and Markets. (2023). Oncology Drugs Market.
[2] Merck Annual Report. (2022).
[3] WHO. (2020). Cancer Fact Sheet.